AIMS Bioscience, a drug development consulting company led by CEO Dongseok Lim, announced on the 28th that it has signed a strategic agreement with Calici, an AI-driven drug discovery platform company headed by CEO Jae-Mun Choi, to enhance efficiency in drug development.

Calici operates as a Bio-IT convergence company, combining domain knowledge in protein therapeutics with advanced AI technologies through its open platform, Pharmaco-Net®. The platform provides data-driven services and solutions designed to accelerate and optimize the drug discovery process.

Through this collaboration, the two companies plan to establish a cooperative network in the field of drug research and development, leveraging their respective infrastructures to improve efficiency, accuracy, and overall project outcomes.

AIMS Bioscience intends to integrate Pharmaco-Net® into its consulting projects, particularly in areas related to protein structure-based small-molecule drug candidates and functional compounds. By doing so, the company expects to advance critical tasks such as mode-of-action analysis, drug optimization, and model application with greater precision and speed.

CEO Dongseok Lim of AIMS Bioscience stated, “We believe this collaboration with Calici represents a meaningful step forward in increasing the likelihood of success in drug development. By utilizing AI platforms, we can not only reduce time and cost but also enhance the completeness and reliability of our projects.”